Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial

By Public Technologies
  • Viking Therapeutics presented new results from its Phase 2 VENTURE obesity trial of injectable VK2735 at ObesityWeek 2026.
  • Most treated participants improved their obesity classification over 13 weeks, outperforming placebo; none shifted to a higher BMI category.
  • Participants whose obesity classification improved showed greater reductions in cardiovascular and metabolic risk markers than those whose classification remained unchanged.
  • The ongoing Phase 3 VANQUISH program evaluates weekly injectable VK2735, with trial completion expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151205PR_NEWS_USPR_____LA98030) on November 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.